Company intelligence / Profile preview

Stämm

Ownership: Private
Employees: ~100
Development stage: Commercial

Overview

Stämm has developed an advanced biomanufacturing platform using modular microfluidics and 3D printing to enable automated, continuous, scalable production of biologics and cell therapies. Their technology aims to reduce costs, increase productivity, and make bioprocessing more sustainable. The company does not develop its own therapeutics but provides enabling solutions for others in the biotech/pharma sector.

Modalities: Monoclonal antibodies (mAbs)Cell therapies
Industry: Contract Manufacturing Organization

Partnerships

No specific major pharmaceutical or biotech partnerships named in available sources. However, they mention working with companies and academic institutions involved in mAbs and CGT R&D that require cell line optimization and scale-up.

Beyond the preview

Go deeper on Stämm.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Stämm.

Explore the full profile